PhotoMedex, Inc. and Galderma Laboratories to Co-Promote Actinic Keratosis Treatment

Published: Jan 11, 2010

MONTGOMERYVILLE, Pa.--(BUSINESS WIRE)--PhotoMedex (Nasdaq: PHMD) and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”). Under the terms of the agreement, PhotoMedex’ sales force will promote Galderma’s drug Metvixia® (methyl aminolevulinate) Cream, 16.8% (“Metvixia”) and Galderma’s Aktilite® CL128 LED (light-emitting diode) lamp to healthcare professionals, including dermatologists, plastic surgeons and cosmetic surgeons throughout the United States. Galderma will provide marketing support and distribution. The three-year agreement begins in January; no financial terms have been disclosed.

Back to news